BIONTECH
BioNTech is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline.
BIONTECH
Industry:
Biopharma Biotechnology Pharmaceutical
Founded:
2008-01-01
Address:
Mainz, Rheinland-Pfalz, Germany
Country:
Germany
Website Url:
http://www.biontech.de
Total Employee:
1001+
Status:
Active
Contact:
+49 6131 90-840
Email Addresses:
[email protected]
Total Funding:
1.74 B USD
Technology used in webpage:
SPF Domain Not Resolving Mobile Non Scaleable Content Amazon Organization Schema IPv6 ReCAPTCHA JsDelivr Cloudflare JS US Privacy User Signal Mechanism
Similar Organizations
Celator Pharmaceuticals
Celator Pharmaceuticals is a biopharmaceutical company developing therapies to treat cancer, using the drug ratio technology platform.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2021-11-09 | PhagoMed | PhagoMed acquired by BioNTech | N/A |
| 2021-07-19 | Kite - TCR therapy | Kite - TCR therapy acquired by BioNTech | N/A |
| 2020-01-16 | Neon Therapeutics | Neon Therapeutics acquired by BioNTech | 67 M USD |
Investors List
German Federal Ministry of Education and Research (BMBF)
German Federal Ministry of Education and Research (BMBF) investment in Grant - BioNTech
Temasek Holdings
Temasek Holdings investment in Post-IPO Equity - BioNTech
European Investment Bank
European Investment Bank investment in Post-IPO Debt - BioNTech
European Investment Bank
European Investment Bank investment in Post-IPO Debt - BioNTech
Bill & Melinda Gates Foundation
Bill & Melinda Gates Foundation investment in Venture Round - BioNTech
Fidelity Management and Research Company
Fidelity Management and Research Company investment in Series B - BioNTech
Platinum Asset Management
Platinum Asset Management investment in Series B - BioNTech
MiraeAsset Financial Group
MiraeAsset Financial Group investment in Series B - BioNTech
Jebsen Capital
Jebsen Capital investment in Series B - BioNTech
Invus
Invus investment in Series B - BioNTech
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2022-02-02 | MediGene | BioNTech investment in Post-IPO Equity - MediGene | 26 M EUR |
| 2022-01-25 | InstaDeep | BioNTech investment in Series B - InstaDeep | 100 M USD |
Official Site Inspections
http://www.biontech.de Semrush global rank: 291.45 K Semrush visits lastest month: 228.31 K
- Host name: a23-218-224-19.deploy.static.akamaitechnologies.com
- IP address: 23.218.224.19
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "BioNTech"
BioNTech - Wikipedia
BioNTech was founded in 2008 based on research by Uğur Şahin, Özlem Türeci, [8] and Christoph Huber, [9] with a seed investment of €180 million [10] from MIG Capital, a Munich …See details»
BioNTech Org Chart + Executive Team - The Official Board
See the executive team of BioNTech and its org chart, featuring 42 leaders like Ugur Sahin, Jens Holstein and Sierk Poetting . Toggle navigation The Official Board. Search. ... BioNTech Org …See details»
Management Report on the Group and the Company for the 2020 …
Biontech – Wikipedia
Biontech wurde 2008 auf der Grundlage langjähriger Forschungsarbeiten von Uğur Şahin, Özlem Türeci und Christoph Huber als Biontech RNA Pharmaceuticals GmbH gegründet. Sahin und …See details»
BioNTech - The Org
BioNTech was founded in 2008 on the understanding that every cancer patient’s treatment should be individualized. Their vision is to provide patient-specific immunotherapies worldwide. …See details»
BioNTech SE Company Profile - Overview - GlobalData
BioNTech SE (BioNTech) is a biotechnology company that develops immunotherapies for cancer and infectious diseases. The company's primary activities involve harnessing the immune …See details»
BioNTech - Crunchbase Company Profile & Funding
Organization. BioNTech . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. BioNTech is a biopharmaceutical company that develops cancer therapeutics for infectious …See details»
From Discovery to Delivery – Meet our Senior Team
Prior to joining BioNTech, she built and led a global shared services organization at Merck KGaA that provides global end-to-end finance, human resources, and procurement services. Lynn holds a Diploma in Business Administration with a …See details»
Overview - BioNTech
We at BioNTech believe that adhering to the highest Corporate Governance standards positively impacts our performance and we put great importance on building trust with investors, the …See details»
BioNTech | Our mission: basic research in mRNA technology and …
BioNTech’s portfolio contains more than 25 product candidates in clinical trials. In pursuit of changing the treatment paradigm with individualized cancer therapies, our pipeline …See details»
BioNTech Clinical Trials | Advancing Health Through Innovation
Welcome to BioNTech clinical trials. At BioNTech, we are committed to improving the health of people worldwide by developing novel medicines to address cancer, infectious diseases and …See details»
BioNTech takes over CureVac in $1.25 billion all-stock deal among …
2 days ago June 12 (Reuters) - German biotech firm BioNTech (22UAy.DE), opens new tab has agreed to acquire domestic peer CureVac (5CV.DE), opens new tab for about $1.25 billion …See details»
Biontech: Vorbild für die deutsche Industrie - Wirtschaft - SZ.de
1 day ago Biontech wurde mit dem Deutschen Nationalpreis 2025 ausgezeichnet und zeigt durch Kooperationen und Übernahmen, wie Innovationen in der Biotechnologie den Standort …See details»
Press Release - investors.biontech.de
2 days ago [email protected]. CureVac: Media and Investor Relations [email protected]. BioNTech SE. An der Goldgrube 12. 55131 Mainz, …See details»
Übersicht - BioNTech
Wir legen großen Wert darauf, Vertrauen bei Investoren, der Öffentlichkeit und anderen Stakeholdern aufzubauen. BioNTech SE baut auf eine transparente …See details»
Unser Führungskräfteteam - BioNTech
Oliver Hennig ist Senior Vice President Operations bei BioNTech SE und Managing Director der BioNTech Manufacturing GmbH. In diesen Positionen ist er für das BioNTech …See details»
BioNTech Announces First Quarter 2025 Financial Results and …
Mar 31, 2025 Revenues reported were €182.8 million for the three months ended March 31, 2025, compared to €187.6 million for the comparative prior year period. Revenues during the …See details»
BioNTech | All unsere weltweiten Standorte auf einen Blick
BioNTech SE An der Goldgrube 12 55131 Mainz, Deutschland. T: +49 6131 9084-0 F: +49 6131 9084-2121 M: [email protected]. Unternehmen Über uns Forschung & Innovation Unsere …See details»
BioNTech Announces Appointment of Ramón Zapata to …
Mainz, Germany, May 5, 2025 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that the Supervisory Board has appointed …See details»
BioNTech | Collaborators
TRON is a biopharmaceutical research organization that pursues the development of new diagnostics and drugs to treat cancer and other severe diseases. TRON was founded to …See details»